ConverGene has entered into a Sponsored Research Agreement with University of Maryland, Baltimore. Under this agreement University of Maryland School of Medicine Professor Curt I. Civin, M.D., who is associate dean for research and director of the Center For Stem Cell Biology & Regenerative Medicine, will investigate the in vivo anti-leukemic effects of ConverGene’s lead drug candidates, CG223 and CG250. Acute Myelogenous Leukemia (AML) is a likely first disease target for these compounds.
{iframe}https://globenewswire.com/news-release/2017/01/25/910808/0/en/ConverGene-Announces-Sponsored-Research-Agreement-with-University-of-Maryland-Baltimore-to-Evaluate-First-in-class-Anti-cancer-Agents.html{/iframe}